Breaking News, Collaborations & Alliances

Oncodesign, UCB In Early Development Pact

Will leverage Nanocyclix platform to develop therapies for neurodegenerative diseases

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Oncodesign has entered into a research collaboration and exclusive license option with UCB leveraging Oncodesign’s Nanocyclix technology platform for next generation kinase inhibitors, and UCB’s expertise in neurology, to develop therapeutic solutions for neurodegenerative disorders. Oncodesign will apply its Nanocyclix technology on a kinase target selected by UCB with the aim of discovering potent and selective inhibitors that cross the blood brain barrier.   UCB has an exclusive option to lic...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters